Clinical trials: sponsored by Addpharma Inc.
Mixed Dyslipidemia
A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.
- Trial name
- NCT06932705
- Testing
- PA-111, PA-111A
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gastroesophageal Reflux Disease (GERD)
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.
- Trial name
- NCT06916130
- Testing
- AD-120A, AD-120
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Primary Hypercholesterolaemia
A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.
- Trial name
- NCT06884098
- Testing
- AD-228B, AD-2284
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hyperlipidemias
A Study to Assess the Safety and Pharmacokinetics of AD-104-A
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-104-A
- Trial name
- NCT05703282
- Testing
- AD-104-A
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gastro Esophageal Reflux
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-212-A in healthy subjects.
- Trial name
- NCT06025773
- Testing
- Lansoprazole 15 mg, Lansoprazole 15mg/Calcium carbonate 600mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hyperlipidemias
A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-221 in healthy male subjects.
- Trial name
- NCT05202405
- Testing
- AD-221, AD-221A and AD-221B
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gastroesophageal Reflux Disease
A Study to Compare PK, PD and Safety of the AD-214 and AD-2141
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214 to AD-2141 in healthy volunteers.
- Trial name
- NCT05062876
- Testing
- AD-214, AD-2141
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gastroesophagus Reflux Disease
A Study to Compare PK, PD and Safety of the AD-213-A and AD-2131
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-213-A to AD-2131 in healthy volunteers.
- Trial name
- NCT04690868
- Testing
- AD-213-A, AD-2131
- Where
- South Korea
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Embolism and Thrombosis
A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109 in healthy male subjects.
- Trial name
- NCT05128591
- Testing
- Rivaroxaban 18mg Oral Tablet, Rivaroxaban 20 MG Oral Tablet
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gastroesophagus Reflux Disease
A Study to Compare PK, PD and Safety of the AD-213-B and AD-2132
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-213-B to AD-2132 in healthy volunteers.
- Trial name
- NCT04755985
- Testing
- AD-213-B, AD-2132
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gastroesophageal Reflux Disease
A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214 10/600mg to Rabeprazole 10mg in healthy volunteers.
- Trial name
- NCT04494243
- Testing
- AD-214 10/600mg, Rabeprazole 10mg
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gastroesophageal Reflux Disease
A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214-02 to Rabeprazole in healthy volunteers.
- Trial name
- NCT04622358
- Testing
- AD-214-02, Rabeprazole
- Where
- South Korea
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hypertension
Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102
The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2101 and AD-2102 in healthy male subjects.
- Trial name
- NCT04600284
- Testing
- AD-2101, AD-2102, AD-2101 + AD-2102
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Gastritis
A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-206 to Esomeprazole in healthy male volunteers.
- Trial name
- NCT03980756
- Testing
- AD-206 20mg, Esomeprazole 20mg, AD-206 40mg
- Where
- South Korea
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Androgenetic Alopecia
To Evaluate the Pharmacokinetics and Safety of AD-208
To evaluate pharmacokinetics and safety of AD-208.
- Trial name
- NCT04214808
- Testing
- AD-208, Avodart Soft Capsule 0.5mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Pain
Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112
A phase I clinical trial to evaluate the pharmacokinetic interactions and safety between AD-2111 and AD-2112
- Trial name
- NCT04375865
- Testing
- AD-2111, AD-2112
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Osteoporosis
Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-101 in healthy volunteers
- Trial name
- NCT03764462
- Testing
- AD-101 45mg, Raloxifene 60mg
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Osteoporosis
Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-102 in healthy male subjects
- Trial name
- NCT03824171
- Testing
- Raloxifene 60mg/Cholecalciferol 800IU, AD-102
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hyperlipidemias, Hypertension
Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072
The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2071 and AD-2072 in healthy male volunteers.
- Trial name
- NCT03632668
- Testing
- AD-2071 10/20mg, AD-2072 80/5mg, AD-2071 10/20mg + AD2072 80/5mg
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hyperlipidemias, Hypertension
Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012
The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2011 and AD-2012 in healthy male volunteers.
- Trial name
- NCT03586037
- Testing
- AD-2011 10/20 mg, AD-2012 80mg, AD-2011 10/20 mg + AD-2012 80mg
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.